Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.75 |
| ▸ | FBP1 | P09467 | 4/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.69 |
| ▸ | KDR | P35968 | 7/20 | 0.66 |
| ▸ | GAK | O14976 | 2/20 | 0.66 |
| ▸ | ABL1 | P00519 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CDK1 | P06493 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646431 | 0.88 | FBP1 (0.70) | EGFRFBP1ERBB2ERBB4KDR | |
| Erlotinib SCHEMBL13087124 | 0.86 | EGFR (0.78) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL13646434 | 0.85 | EGFR (0.68) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL22367416 | 0.83 | FBP1 (1.00) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL13646436 | 0.83 | KDR (0.67) | EGFRERBB2ERBB4KDRGAK | |
| SCHEMBL3008965 | 0.82 | FBP1 (1.00) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL13646416 | 0.82 | EGFR (0.63) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL8349430 | 0.82 | EGFR (0.91) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL4232360 | 0.81 | FBP1 (0.84) | EGFRFBP1ERBB2ERBB4KDR | |
| Erlotinib SCHEMBL13087052 | 0.81 | EGFR (0.86) | EGFRFBP1ERBB2ERBB4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | EGFR 19/4885FBP1 3745/4885ERBB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.